Main Category: Prostate / Prostate Cancer
Also Included In: Regulatory Affairs / Drug Approvals; Cancer / Oncology; Urology / Nephrology
Article Date: 21 Mar 2011 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }());
email to a friend 
printer friendly 
opinions 
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced it has received marketing authorization from the European Commission for JEVTANA® (cabazitaxel) in combination with prednisone/prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen.1 JEVTANA is the first approved agent to significantly extend overall survival in mHRPC patients whose disease has progressed during or after treatment containing docetaxel (15.1 months median overall survival vs 12.7 months in the mitoxantrone arm; HR=0.70 (95% CI: 0.59-0.83); P<0.0001).1
The approval from the European Commission followed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The decision is based on the results from the Phase III TROPIC clinical study involving 755 patients with mHRPC previously treated with a docetaxel-containing treatment regimen. The European Commission decision is applicable to the 27 Member States of the European Union (EU) as well as Iceland, Lichtenstein and Norway. JEVTANA was previously approved in the US, Israel, Curaçao and Brazil.
"JEVTANA in combination with prednisone/prednisolone reduced the risk of death by nearly one third and extended progression-free survival compared to mitoxantrone, an active comparator," said Debasish Roychowdhury, M.D., Senior Vice President and Head, Global Oncology Division, sanofi-aventis. "The European approval of JEVTANA offers new hope for patients across Europe with limited treatment options should their disease progress following first-line therapy."
Incidence of Prostate Cancer
Worldwide, prostate cancer ranks third in cancer incidence and sixth in cancer mortality in men. In the U.S., prostate cancer remains the second most common cause of cancer death among men after lung cancer. In 2009, an estimated 192,000 new cases were anticipated in the U.S., while 27,000 men were expected to have died from the disease. Latest figures show that an estimated 300,000 new cases of prostate cancer appear in the European Union every year2 .For many patients with prostate cancer, their disease continues to progress despite prior treatment - including surgical and/or hormonal castration followed by chemotherapy. Metastatic prostate cancer indicates that the cancer has spread to the lymph nodes or other parts of the body, particularly the bones. Castration resistant/hormone-refractory prostate cancer means that the cancer has continued to grow despite the suppression of male hormones that fuel the growth of prostate cancer cells. An estimated 10-20 percent of patients with prostate cancer are diagnosed when the cancer has already metastasized.
About the TROPIC TrialResults from the TROPIC trial demonstrated a 30 percent [HR=0.70 (95% CI: 0.59-0.83); P<0.0001] reduction in risk of death from mHRPC among patients taking JEVTANA in combination with prednisone or prednisolone, compared with a chemotherapy regimen consisting of a standard dose of mitoxantrone and prednisone or prednisolone. In addition, the median survival of patients receiving JEVTANA was 15.1 months, 2.4 months higher than patients receiving mitoxantrone. 2
In the TROPIC Study, the most common (= 10%) adverse events grade >3 were anemia, leukopenia, neutropenia, thrombocytopenia and diarrhea. The most common (= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia and diarrhea.
About JEVTANA® (cabazitaxel Injection)
JEVTANA is a semi-synthetic taxane and works differently than docetaxel and paclitaxel. An antineoplastic agent, it acts by disrupting the microtubular network in cells. It binds to tubulin and promotes the assembly of tubulin into microtubules while simultaneously inhibiting their disassembly. This leads to the stabilization of microtubules. JEVTANA demonstrated a broad spectrum of antitumor activity against advanced solid tumours xenografted in mice. JEVTANA is active in docetaxel sensitive tumours. In addition, JEVTANA demonstrated activity in tumor models insensitive to chemotherapy, including docetaxel.
About sanofi-aventis Oncology
Based in Cambridge, Massachusetts, and Vitry, France, sanofi-aventis Oncology, a division of sanofi-aventis, is translating science into effective cancer therapeutics to address unmet medical needs for patients with cancer. Starting with a deep understanding of the mechanisms by which cancer develops, grows and spreads, the company employs innovative approaches in drug discovery, clinical development and partnerships to bring the right medicines to the right patients with the goal of helping cancer patients live healthier and longer lives.
Sanofi-aventis Oncology is committed to the pursuit of science and innovative cancer therapies. We believe in partnership with leading experts, and combining that expertise with our own internal scientific strength and heritage. There are currently more than 10 compounds in clinical development including small molecules and biological agents.
References
1. De Bono et al. Lancet 2010; 376:1147-54
2. European Cancer Patient Coalition Accessed here. on 18 March 2011
Source:
Sanofi-aventis
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Privacy Policy | Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.
No comments:
Post a Comment